Loading
OI
Oncorus, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 25 May 2022.
Oncorus, Inc.: what insiders have been doing
Oncorus, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Nothing new has been filed by managers of Oncorus, Inc. in twelve months, the latest record being from 30 December 2022.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
19
Thresholds
n/a
Buy Volume
€97,235
5 ops. · all time
Sell Volume
€512,351
11 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
Net income-US$66.7M
Last declaration on 30 December 2022
Declarations19 total
24,757 shares@ US$0.2515.7% of flowCommon StockSEC:0001193805-22-001817:0
28,977 shares@ US$0.2719.8% of flowCommon StockSEC:0001193805-22-001793:4
3,692 shares@ US$0.282.6% of flowCommon StockSEC:0001193805-22-001793:0
3,693 shares@ US$0.282.6% of flowCommon StockSEC:0001193805-22-001793:1
909 shares@ US$0.280.6% of flowCommon StockSEC:0001193805-22-001793:2
28,977 shares@ US$0.2719.8% of flowCommon StockSEC:0001193805-22-001793:3
7,136 shares@ US$0.274.9% of flowCommon StockSEC:0001193805-22-001793:5
44,394 shares@ US$0.2932.8% of flowCommon StockSEC:0001193805-22-001764:0
934 shares@ US$0.411.0% of flowCommon StockSEC:0001193805-22-001734:0
3,777 shares@ US$1.2020.5% of flowCommon StockSEC:0001209191-22-031907:0
Canonical exit: 23 Aug 2022 (T+90)
1,610 shares@ US$1.208.8% of flowCommon StockSEC:0001209191-22-031614:0
Canonical exit: 18 Aug 2022 (T+90)
1 shares@ US$1.200.0% of flowCommon StockSEC:0001209191-22-030495:0
Canonical exit: 15 Aug 2022 (T+90)
14,094 shares@ US$1.0870.7% of flowCommon StockSEC:0001209191-22-029259:0
Canonical exit: 10 Aug 2022 (T+90)
32,500 shares@ US$1.8143.2% of flowCommon StockSEC:0001209191-21-066003:0
15,000 shares@ US$5.797100.0% of flowCommon StockSEC:0001209191-21-065058:0
Canonical exit: 14 Feb 2022 (T+90)
43,707 shares@ US$1.8156.8% of flowCommon StockSEC:0001209191-21-061525:0
12,899 shares@ US$16.6933.4% of flowCommon StockSEC:0001209191-21-037764:0
35,561 shares@ US$1.8110.0% of flowCommon StockSEC:0001209191-21-035931:0
22,755 shares@ US$15.9456.6% of flowCommon StockSEC:0001209191-21-029987:0
19 of 19 declarations
About Oncorus, Inc.
Oncorus, Inc. (ticker: ONCR) is a U.S.-based biotechnology company listed on the NASDAQ market in the United States. For French-, Belgian- and Swiss-based investors, Oncorus is best understood as an early-stage, development-focused biotech rather than a revenue-generating commercial healthcare company. The company was originally built around oncology innovation, with an emphasis on gene- and immunotherapy approaches, and later narrowed its strategy to prioritize intravenously administered self-amplifying RNA medicines aimed at treating cancer. ([nasdaq.com](https://www.nasdaq.com/press-release/oncorus-announces-portfolio-reprioritization-to-focus-on-iv-administered-self?utm_source=openai))
Operationally, Oncorus remains a research and development story. Its core business lines are preclinical and clinical development, platform validation, and portfolio advancement rather than manufacturing scale or broad commercial sales. Public disclosures indicate that the company reprioritized its pipeline to focus on its lead RNA-based program, while the progression of additional programs depended on incremental financing or strategic collaboration. That makes the investment case highly event-driven: valuation is driven primarily by data readouts, funding runway, and partnership potential. ([nasdaq.com](https://www.nasdaq.com/press-release/oncorus-announces-portfolio-reprioritization-to-focus-on-iv-administered-self?utm_source=openai))
Read moreShow less
In competitive terms, Oncorus operates in one of the most crowded and capital-intensive areas of biotechnology. It competes indirectly with larger pharmaceutical groups, well-funded RNA platforms, and oncology-focused biotechs pursuing similar mechanisms or therapeutic areas. Its key differentiator is the self-amplifying RNA platform and the potential to deliver systemic anti-cancer activity through IV administration. If the science translates clinically, that could create meaningful upside; however, the company also faces substantial execution, regulatory, and financing risk, which is typical for a pre-commercial biotech. ([nasdaq.com](https://www.nasdaq.com/press-release/oncorus-announces-portfolio-reprioritization-to-focus-on-iv-administered-self?utm_source=openai))
Geographically, Oncorus is a United States company with operations tied to the Boston-area life sciences cluster. Public announcements show a headquarters relocation to Cambridge, Massachusetts, and later filings and releases reference Andover, Massachusetts, suggesting a footprint in the broader Massachusetts biotech corridor. That location matters strategically because it provides access to scientific talent, research infrastructure, investors, and potential partners. ([nasdaq.com](https://www.nasdaq.com/press-release/oncorus-announces-debt-capital-facility-with-k2-healthventures-with-%2420-million?utm_source=openai))
Recent milestones have centered on portfolio reprioritization and capital management. The company announced a major strategic reset in 2022 to focus on IV-administered self-amplifying RNA medicines, and later disclosures indicated that further development of non-core programs would require additional financing or strategic support. For investors analyzing SEC Form 4 insider transactions, the main takeaway is that insider activity should be interpreted against the backdrop of a small-cap clinical biotech whose near-term value depends more on scientific milestones and funding visibility than on conventional operating performance. ([nasdaq.com](https://www.nasdaq.com/press-release/oncorus-announces-portfolio-reprioritization-to-focus-on-iv-administered-self?utm_source=openai))
